Roche Launches NVIDIA-powered AI Factory to Speed Drug Discovery and Diagnostics
Tuesday, March 17, 2026
Roche has expanded its global artificial intelligence infrastructure by launching a large-scale AI factory built on advanced computing systems from NVIDIA.
The initiative is aimed at accelerating the development of new therapeutics and diagnostic solutions.
The AI factory includes 2,176 high-performance GPUs installed on premises across the United States and Europe, and is integrated across the company’s value chain. With this addition, Roche’s total GPU capacity, including cloud-based systems, now exceeds 3,500 Blackwell GPUs, marking one of the largest AI computing footprints in the pharmaceutical sector.
This development builds on an ongoing collaboration between Roche and NVIDIA that began in 2023. The expanded infrastructure is intended to improve drug discovery and development by enabling faster data processing and more advanced AI-driven analysis.
The platform supports a wide range of applications across the organisation. In research and development, AI tools are used to connect laboratory experiments with computational models, allowing scientists to test ideas at scale and speed up discovery. In manufacturing, digital twin technology helps optimise production processes and facility design. In diagnostics, advanced computing enables faster analysis of large datasets, including digital pathology, where systems can identify disease patterns in medical images. In digital health, AI frameworks are used to support safe and reliable conversational tools.
The AI factory forms part of Roche’s broader digital transformation strategy, with a focus on integrating AI across operations. By increasing access to high-performance computing, the company aims to enhance its ability to address complex diseases and improve the speed at which new treatments and diagnostic solutions reach patients.
Source: roche.com
